Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-06-2016 | Case Report

Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon

Authors: Władysław B. Gaweł, Grzegorz Helbig, Kinga Boral, Sławomira Kyrcz-Krzemień

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Login to get access

Abstract

Leukemic transformation in patients diagnosed with polycythemia vera (PV) is associated with poor prognosis and median survival not exceeding 3 months. To date only a few cases of post-PV acute lymphoblastic leukemia (ALL) have been reported. A 64-year-old female patient developed ALL 4 years after she had met PV criteria. At PV diagnosis a molecular study was positive for the JAK2V617F mutation. Due to high risk features (history of deep vein thrombosis) she was treated with hydroxyurea (HU) with moderate efficacy. She became anemic and thrombocytopenic with mild leukocytosis while still on HU. Blood and bone marrow smears revealed 40 and 100 % of blast cells, respectively. The immunophenotyping of blasts was consistent with a diagnosis of early precursor B cell ALL. She was found to be positive for the JAK2V617F mutation. Patient received an ALL induction regimen and achieved complete remission with negative minimal residual disease by flow cytometry. The post-chemotherapy study for the JAK2V617F mutation was positive. Patient has remained in remission for 4 months. A suitable donor searching was initiated. Post-PV ALL is an extremely rare phenomenon. Due to poor prognosis, an allogeneic stem cell transplantation should be considered in fit patients who achieved remission.
Literature
1.
go back to reference Tefferi A, Barbui T (2015) Polycythemia vera and essential thromobcythemia: 2015 update on diagnosis, risk stratification and management. Am J Hematol 90:162–167CrossRefPubMed Tefferi A, Barbui T (2015) Polycythemia vera and essential thromobcythemia: 2015 update on diagnosis, risk stratification and management. Am J Hematol 90:162–167CrossRefPubMed
2.
go back to reference Tefferi A, Rumi E, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874–1881CrossRefPubMedPubMedCentral Tefferi A, Rumi E, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27:1874–1881CrossRefPubMedPubMedCentral
3.
go back to reference Finazzi G, Barbui T (2008) Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22:1494–1502CrossRefPubMed Finazzi G, Barbui T (2008) Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22:1494–1502CrossRefPubMed
5.
go back to reference Neilson J, Patton W, Williams M, Mayne EE, Boughton BJ (1994) Polycythaemia rubra vera transforming to acute lymphoblastic leukaemia with a common immunophenotype. J Clin Pathol 47:471–472CrossRefPubMedPubMedCentral Neilson J, Patton W, Williams M, Mayne EE, Boughton BJ (1994) Polycythaemia rubra vera transforming to acute lymphoblastic leukaemia with a common immunophenotype. J Clin Pathol 47:471–472CrossRefPubMedPubMedCentral
6.
go back to reference Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C (2012) Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leukoc Lymphoma 53:1839–1841CrossRef Ohanian M, Leventaki V, Verstovsek S, Estrov Z, Lin P, Yin C (2012) Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leukoc Lymphoma 53:1839–1841CrossRef
7.
go back to reference Czader M, Orazi A (2015) Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms. Am J Clin Pathol 144:188–206CrossRefPubMed Czader M, Orazi A (2015) Acute myeloid leukemia and other types of disease progression in myeloproliferative neoplasms. Am J Clin Pathol 144:188–206CrossRefPubMed
8.
go back to reference Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123:2220–2228CrossRefPubMed Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123:2220–2228CrossRefPubMed
9.
go back to reference Camos M, Cervantes F, Montoto S, Hernandez-Boluda JC, Villamor N, Montserrat E (1999) Acute lymphoid leukemia following polycythemia vera. Leukoc Lymphoma 32:395–398CrossRef Camos M, Cervantes F, Montoto S, Hernandez-Boluda JC, Villamor N, Montserrat E (1999) Acute lymphoid leukemia following polycythemia vera. Leukoc Lymphoma 32:395–398CrossRef
10.
go back to reference Polliack A, Prokocimer M, Matzner Y (1980) Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol 9:211–220CrossRefPubMed Polliack A, Prokocimer M, Matzner Y (1980) Lymphoblastic leukemic transformation (lymphoblastic crisis) in myelofibrosis and myeloid metaplasia. Am J Hematol 9:211–220CrossRefPubMed
11.
go back to reference Wu D, Baodong Y, Shen J, Peng L, Zhong Z, Zhou Y (2015) Acute lymphoblastic leukemia in the course of polycythemia vera: a case report and review of literature. Indian J Hematol Blood Transfus. doi:10.1007/s12288-015-0598-y Wu D, Baodong Y, Shen J, Peng L, Zhong Z, Zhou Y (2015) Acute lymphoblastic leukemia in the course of polycythemia vera: a case report and review of literature. Indian J Hematol Blood Transfus. doi:10.​1007/​s12288-015-0598-y
12.
go back to reference Qasim Z, Nasim L, Parveen R (2014) Transformation of polycythemia vera into acute lymphoblastic leukemia. Int J Pathol 12:91–93 Qasim Z, Nasim L, Parveen R (2014) Transformation of polycythemia vera into acute lymphoblastic leukemia. Int J Pathol 12:91–93
13.
go back to reference Hoffman R, Estren S, Kopel S, Marks SM, McCaffrey RP (1978) Lymphoblastic-like leukemia transformation of polycythemia vera. Ann Intern Med 89:71CrossRefPubMed Hoffman R, Estren S, Kopel S, Marks SM, McCaffrey RP (1978) Lymphoblastic-like leukemia transformation of polycythemia vera. Ann Intern Med 89:71CrossRefPubMed
14.
go back to reference Braich TA, Grogan TM, Hicks MJ, Greenberg BR (1986) Terminal lymphoblastic transformation in polycythemia vera. Am J Med 80:304–306CrossRefPubMed Braich TA, Grogan TM, Hicks MJ, Greenberg BR (1986) Terminal lymphoblastic transformation in polycythemia vera. Am J Med 80:304–306CrossRefPubMed
15.
go back to reference Aitchison R, Black AJ, Greaves MF (1987) Polycythemia rubra vera transforming to acute lymphoblastic leukemia. Clin Lab Haematol 9:201–204CrossRefPubMed Aitchison R, Black AJ, Greaves MF (1987) Polycythemia rubra vera transforming to acute lymphoblastic leukemia. Clin Lab Haematol 9:201–204CrossRefPubMed
16.
go back to reference Anastasi J, Pettenati MJ, Le Beau MM, Kwaan HC, Weil SC (1988) Acute lympoblastic leukemia in a patient with long-standing polycythemia vera: cytogenetic analysis reveals two distinct abnormal clones. Am J Hematol 29:33–37CrossRefPubMed Anastasi J, Pettenati MJ, Le Beau MM, Kwaan HC, Weil SC (1988) Acute lympoblastic leukemia in a patient with long-standing polycythemia vera: cytogenetic analysis reveals two distinct abnormal clones. Am J Hematol 29:33–37CrossRefPubMed
17.
go back to reference Arai Y, Masuda M, Okamura T, Wada M, Motoji T, Mizoguchi H (1996) Polycythemia vera progressing to acute lymphoblastic leuekemia after 13 years. Rinsho Ketsueki 37:1405–1409PubMed Arai Y, Masuda M, Okamura T, Wada M, Motoji T, Mizoguchi H (1996) Polycythemia vera progressing to acute lymphoblastic leuekemia after 13 years. Rinsho Ketsueki 37:1405–1409PubMed
18.
go back to reference Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al (2005) Acute leukemia in polycythemia vera: an analysis of 1838 patients enrolled in a prospective observational study. Blood 105:2664–2670CrossRefPubMed Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C et al (2005) Acute leukemia in polycythemia vera: an analysis of 1838 patients enrolled in a prospective observational study. Blood 105:2664–2670CrossRefPubMed
19.
go back to reference Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29:3907–3913CrossRefPubMed Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD (2011) Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 29:3907–3913CrossRefPubMed
20.
go back to reference Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A et al (2008) Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 80:197–200CrossRefPubMed Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A et al (2008) Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol 80:197–200CrossRefPubMed
Metadata
Title
Acute Lymphoblastic Leukemia Transformation in Polycythemia Vera: A Rare Phenomenon
Authors
Władysław B. Gaweł
Grzegorz Helbig
Kinga Boral
Sławomira Kyrcz-Krzemień
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0673-z

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine